Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodobenzene SCHEMBL334303 | 1.00 | CES1 (0.50) | CES1TPMTCPA1CYP1A2TRPV1 | |
| Iodobenzene SCHEMBL2237441 | 1.00 | CES1 (0.50) | CES1TPMTCPA1CYP1A2TRPV1 | |
| Iodobenzene SCHEMBL15140156 | 0.93 | CES1 (0.45) | CES1TPMTCPA1CYP1A2TRPV1 | |
| Iodobenzene SCHEMBL27524285 | 0.88 | CES1 (0.54) | CES1TPMTCPA1TRPV1PTPN1 | |
| Iodobenzene SCHEMBL28043258 | 0.88 | CES1 (0.41) | CES1TPMTCPA1TRPV1FAAH | |
| Iodobenzene SCHEMBL28291735 | 0.88 | CES1 (0.41) | CES1TPMTCPA1CYP1A2TRPV1 | |
| Trifluoroacetic Acid SCHEMBL28511407 | 0.81 | TPMT (0.44) | CES1TPMTTRPV1 | |
| Pivalate SCHEMBL28120842 | 0.80 | TPMT (0.42) | TPMTCYP1A2HDAC6 | |
| Pivalate SCHEMBL5330607 | 0.80 | TPMT (0.42) | TPMTCYP1A2HDAC6 | |
| Trifluoroacetic Acid SCHEMBL8845061 | 0.79 | TPMT (0.43) | CES1TPMTTRPV1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376447-B1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID PHARMA LTD (IN) | 2017-08-09 | — | — | EP | disclosed |
| US-8466145-B2 | Dipeptidyl peptidase IV inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-06-18 | — | — | US | disclosed |
| US-8389569-B2 | Polyspirane compounds, application thereof in the treatment of malaria or toxoplasmosis and method for preparing same | UNIVERSITE JOSEPH FOURIER (FR) | 2013-03-05 | — | — | US | disclosed |
| EP-2195323-B1 | Polyspirane compounds, use thereof in the treatment of malaria or toxoplasmosis and method for their preparation | UNIV JOSEPH FOURIER (FR) | 2011-12-28 | — | — | EP | disclosed |
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-10-20 | — | — | US | disclosed |
| EP-2376447-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | Orchid Research Laboratories Limited (IN) | 2011-10-19 | — | — | EP | disclosed |
| US-20100298422-A1 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2010-11-25 | — | — | US | disclosed |
| WO-2010079413-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-15 | — | — | WO | disclosed |
| EP-2195323-A2 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | Université Joseph Fourier (FR) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009077677-A2 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298422-A1 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | FLOT1, PHOSPHO1, GPAA1 | CES1 2249/4885TPMT 1020/4885CPA1 3188/4885 |
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | DPP4, DPP7, DPP3 | CES1 61/4885TPMT 257/4885CPA1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.